Use of oral glucose-lowering agents in patients with renal impairment;Utilisation des antidiabétiques oraux en cas d'insuffisance rénale

Revue Medicale Suisse

Volumn 8, Issue 351, 2012, Pages 1614-1620

  Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN; METFORMIN; SULFONYLUREA;

CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CREATININE CLEARANCE; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; SODIUM-GLUCOSE TRANSPORT PROTEINS;

EID: 84865957482     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Detournay B, Simon D, Guillausseau PJ, et al. Chronic kidney disease in type 2 diabetes patients in France : Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. Diabetes Metab 2012 38: 102-12
2. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009 31: 2608-17
3. Whaley-Connell A, Sowers JR, McCullough PA, et al. Diabetes mellitus and CKD awareness : The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009 53( Suppl. 4): S11-21.
4. * Ritz E. Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care 2011 34( Suppl. 2): S330-4.
5. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis : Metabolism and clinical practice. Curr Drug Metab 2011 12: 57-69
6. Ahmed Z, Simon B, Choudhury D. Management of diabetes in patients with chronic kidney disease. Postgrad Med 2009 121: 52-60
7. * Rigalleau V, Beauvieux MC, Gonzalez C, et al. Estimation of renal function in patients with diabetes. Diabetes Metab 2011 37: 359-66
8. McFarland MS, Markley BM, Zhang P, et al. Evaluation of modification of diet in renal disease study and Cockcroft-Gault equations for sitagliptin dosing. J Nephrol 2012 25: 515-22
9. Scheen AJ. Medications in the kidney. Acta Clinica Belgica 2008;63:76-80. (Pubitemid 351729719)
10. Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother 2009 7: 324-42
11. Berwert L, Teta D, Zanchi A. Insuffisance rénale chronique et médicaments antidiabétiques. Rev Med Suisse 2007;3:598-604. (Pubitemid 46479163)
12. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000;26(Suppl. 4):73-85. (Pubitemid 30618360)
13. Lalau JD. Lactic acidosis induced by metformin : Incidence, management and prevention. Drug Saf 2010 33: 727-40
14. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes : A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012 55: 1577-96
15. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71. (Pubitemid 26177181)
16. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011 50: 81-98
17. Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996;31:111-9. (Pubitemid 26252690)
18. Scheen AJ. Metformin and lactic acidosis. Acta Clin Belg 2011 66: 329-31
19. ** Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011 34: 1431-7
20. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489-503. (Pubitemid 29296595)
21. Philbrick AM, Ernst ME, McDanel DL, et al. Metformin use in renal dysfunction : Is a serum creatinine threshold appropriate ? Am J Health Syst Pharm 2009 66: 2017-23
22. Pongwecharak J, Tengmeesri N, Malanusorn N, et al. Prescribing metformin in type 2 diabetes with a contraindication : Prevalence and outcome. Pharm World Sci 2009 31: 481-6
23. Emslie-Smith AM, Boyle DI, Evans JM, et al. Contraindications to metformin therapy in patients with Type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-8. (Pubitemid 32738698)
24. Vasisht KP, Chen SC, Peng Y, et al. Limitations of metformin use in patients with kidney disease : Are they warranted ? Diabetes Obes Metab 2010 12: 1079-83
25. Kennedy L, Herman WH. Renal status among patients using metformin in a primary care setting. Diabetes Care 2005;28:922-4. (Pubitemid 40434496)
26. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010 170: 1892-9
27. Nye HJ, Herrington WG. Metformin : The safest hypoglycaemic agent in chronic kidney disease ? Nephron Clin Pract 2011 118: c380-3.
28. Holstein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point ? Diabetologia 2005;48:2454-9. (Pubitemid 41738207)
29. Pilmore HL. Review : Metformin : Potential benefits and use in chronic kidney disease. Nephrology (Carlton) 2010 15: 412-8
30. Rocha A, Almeida M, Santos J, et al. Metformin in patients with chronic kidney disease : Strengths and weaknesses. J Nephrol 2012 epub ahead of print.
31. Holstein A, Hammer C, Hahn M, et al. Severe sulfonylurea-induced hypoglycemia : A problem of uncritiBibliographie cal prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 2010 9: 675-81
32. Schejter YD, Turvall E, Ackerman Z. Characteristics of patients with sulphonurea-induced hypoglycemia. J Am Med Dir Assoc 2012 13: 234-8
33. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000 35: 500-5
34. Weir MA, Gomes T, Mamdani M, et al. Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide : A population-based nested case-control study. Nephrol Dial Transplant 2011 26: 1888-94
35. Aspinall SL, Zhao X, Good CB, et al. Intervention to decrease glyburide use in elderly patients with renal insufficiency. Am J Geriatr Pharmacother 2011 9: 58-68
36. Rosenkranz B, Profozic V, Metelko Z, et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996;39:1617-24. (Pubitemid 26397377)
37. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72. (Pubitemid 351831357)
38. Hung AM, Roumie CL, Greevy RA, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int 2012 81: 698-706
39. Scott LJ. Repaglinide : A review of its use in type 2 diabetes mellitus. Drugs 2012 72: 249-72
40. McLeod JF. Clinical pharmacokinetics of nateglinide : A rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004;43:97-120. (Pubitemid 38283133)
41. Schumacher S, Abbasi I, Weise D, et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001;57:147-52. (Pubitemid 32449136)
42. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003;26:886-91. (Pubitemid 36929360)
43. Devineni D, Walter YH, Smith HT, et al. Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol 2003;43:163-70. (Pubitemid 36125943)
44. Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007;46:93-108. (Pubitemid 46193056)
45. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones : An assessment from bench to bedside. Kidney Int 2006;70:1223-33. (Pubitemid 44435173)
46. Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects : Facts, fiction and putative management strategies. Drug Saf 2007;30:741-53. (Pubitemid 47347350)
47. Bolignano D, Zoccali C. Glitazones in chronic kidney disease : Potential and concerns. Nutr Metab Cardiovasc Dis 2012 22: 167-75
48. Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012 13: 81-99
49. * Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010 12: 648-58
50. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012 51: 501-14
51. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862-4. (Pubitemid 47036366)
52. He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet 2012 51: 147-62
53. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011 50: 253-65
54. Ito M, Abe M, Okada K, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011 58: 979-87
55. Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011 65: 1230-9
56. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55. (Pubitemid 351850898)
57. Lukashevich V, Schweizer A, Shao Q, et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment : A prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011 13: 947-54
58. Kothny W, Shao Q, Groop PH, et al. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal insufficiency. Diabetes Obes Metab 2012 epub ahead of print.
59. Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Exp Opin Drug Metab Toxicol 2011 7: 1561-76
60. * Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011 13: 939-46
61. Scheen AJ. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opin Drug Metab Toxicol 2012 8: 383-94
62. Scheen AJ, Radermecker RP, Ernest P, et al. Inhibiteurs du cotransporteur du glucose SGLT2 rénal pour traiter le diabète de type 2. Rev Med Suisse 2011 7: 1621-9
63. Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012 epub ahead of print.